These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23047226)

  • 21. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
    Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
    Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4]triazoles as inhibitors of transforming growth factor beta1 type 1 receptor.
    Kim DK; Kim J; Park HJ
    Bioorg Med Chem; 2004 May; 12(9):2013-20. PubMed ID: 15080905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
    Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
    J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
    Reichelt A; Bailis JM; Bartberger MD; Yao G; Shu H; Kaller MR; Allen JG; Weidner MF; Keegan KS; Dao JH
    Eur J Med Chem; 2014 Jun; 80():364-82. PubMed ID: 24793884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.
    Boys ML; Bian F; Kramer JB; Chio CL; Ren XD; Chen H; Barrett SD; Sexton KE; Iula DM; Filzen GF; Nguyen MN; Angell P; Downs VL; Wang Z; Raheja N; Ellsworth EL; Fakhoury S; Bratton LD; Keller PR; Gowan R; Drummond EM; Maiti SN; Hena MA; Lu L; McConnell P; Knafels JD; Thanabal V; Sun F; Alessi D; McCarthy A; Zhang E; Finzel BC; Patel S; Ciotti SM; Eisma R; Payne NA; Gilbertsen RB; Kostlan CR; Pocalyko DJ; Lala DS
    Bioorg Med Chem Lett; 2012 May; 22(10):3392-7. PubMed ID: 22542194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
    Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE
    J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
    Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti-cardiac fibrosis activity.
    Yang YX; Guo J; Liu C; Nan JX; Wu YL; Jin CH
    Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400131. PubMed ID: 38678538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of N-(3-fluorobenzyl)-4-(1-(methyl-d
    Kang BN; Kang HJ; Kim S; Lee J; Lee J; Jeong HJ; Jeon S; Shin Y; Yoon C; Han C; Seo J; Yun J
    Bioorg Med Chem Lett; 2023 Apr; 85():129205. PubMed ID: 36858078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors.
    Arai M; Hanada M; Moriyama H; Ohmoto H; Miyake T; Naka K; Sawa M
    Bioorg Med Chem Lett; 2024 Aug; 108():129797. PubMed ID: 38759932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
    J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel, selective and potent Chk2 inhibitors.
    Larson G; Yan S; Chen H; Rong F; Hong Z; Wu JZ
    Bioorg Med Chem Lett; 2007 Jan; 17(1):172-5. PubMed ID: 17035018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
    J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
    Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
    Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
    Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
    Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
    Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
    J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.